Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Brief Summary: This randomized phase II trial studies how well paclitaxel when given together with or without pazopanib hydrochloride works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that is persistent or has come back. Drugs used in chemotherapy, such as paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking blood flow to the tumor or by blocking some of the enzymes needed for cell growth. It is not yet known whether paclitaxel is more effective when given with or without pazopanib hydrochloride in treating ovarian epithelial, fallopian tube, and peritoneal cavity cancer.


Options:
A: Arm Label: Arm I (paclitaxel and placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo | Arm Label: Arm II (paclitaxel and pazopanib hydrochloride); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Pazopanib Hydrochloride | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Pazopanib Hydrochloride; Assigned to Arm(s): Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (paclitaxel and placebo)
B: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: atezolizumab + bevacizumab + placebo; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: placebo | Arm Label: atezolizumab + bevacizumab + acetylsalicylic acid; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: atezolizumab, Drug: acetylsalicylic acid | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: atezolizumab; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid, atezolizumab + bevacizumab + placebo | Intervention Type: DRUG; Name: acetylsalicylic acid; Assigned to Arm(s): atezolizumab + bevacizumab + acetylsalicylic acid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): atezolizumab + bevacizumab + placebo
D: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin

Answer: A